DDInter166 DDInter1376
A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also known as CD25 antigen) on the surface of activated T-lymphocytes. It is a 144 kDa glycoprotein obtained from fermentation of an established mouse myeloma cell line genetically engineered to express plasmids containing the human heavy and light chain constant region genes and mouse heavy and light chain variable region genes encoding the RFT5 antibody that binds selectively to the IL-2R alpha.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Basiliximab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Basiliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ocrelizumab
Basiliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anakinra
Basiliximab {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Basiliximab {u} may lead to a major life threatening interaction when taken with {v} Infliximab
Basiliximab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Basiliximab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Basiliximab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra
Basiliximab may lead to a major life threatening interaction when taken with Upadacitinib
Basiliximab may lead to a major life threatening interaction when taken with Infliximab